Adeneye A K, Mafe M A, Appelt B, Idowu E T, Akande D O
Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
Res Social Adm Pharm. 2006 Mar;2(1):83-95. doi: 10.1016/j.sapharm.2005.12.004.
Schistosomiasis is highly endemic in Nigeria. However, very little is known about the usage and social marketing of praziquantel in the control of schistosomiasis in endemic communities and on the persons willingness to pay for the drug to support its extensive use and thus aid control efforts in Nigeria.
The study examined the willingness of people in a hyperendemic community, to pay for treatment with praziquantel before and after provision of the drug, with a view to assess the feasibility of achieving widespread coverage.
Data were collected through focus group discussions among household heads and other adult family members and through the use of a questionnaire to survey household heads in Imala-Odo, a community hyperendemic for schistosomiasis, in southwest Nigeria. The main outcome measure was the respondents' willingness to pay for schistosomiasis treatment.
The results showed that in contrast to the 92.3% of respondents who expressed willingness to buy the drug in the preintervention study, only 46.5% actually purchased the drug during intervention for the treatment of their infected household members. The respondents' level of education, occupation, and income influenced their willingness to pay (P<.05). Statistical tests showed that those willing to pay for treatment had a higher income score than those unwilling to do so. Most respondents preferred their community head and reliable persons chosen by the community as convenient outlets for drug distribution. The number of household members respondents were willing to treat increased from 4 to 6 at N320.00 (US $2.52) in the preintervention and postintervention phases, respectively. Gender factor was found to influence the respondents' perceived average treatment cost; the females wanted N300.00 (US $2.36) against N100.00 (US $0.79) among the males.
Efforts need to be made and sustained to ensure that all families can afford to praziquantel drug to achieve the ultimate goal of controlling the infection in endemic communities of Nigeria.
血吸虫病在尼日利亚高度流行。然而，对于吡喹酮在流行社区控制血吸虫病中的使用及社会营销情况，以及人们为支持该药广泛使用从而助力尼日利亚控制工作而支付该药费用的意愿，了解甚少。
本研究调查了高度流行社区居民在提供药物前后为吡喹酮治疗付费的意愿，以评估实现广泛覆盖的可行性。
通过与户主及其他成年家庭成员进行焦点小组讨论，并使用问卷对尼日利亚西南部血吸虫病高度流行社区伊马拉 - 奥多的户主进行调查来收集数据。主要结局指标是受访者为血吸虫病治疗付费的意愿。
结果显示，与干预前研究中92.3%表示愿意购买该药的受访者相比，干预期间实际为感染家庭成员购买该药治疗的受访者仅占46.5%。受访者的教育程度、职业和收入影响其付费意愿（P<0.05）。统计检验表明，愿意为治疗付费者的收入得分高于不愿付费者。大多数受访者倾向于由社区负责人和社区选定的可靠人员作为方便的药物分发渠道。在干预前和干预后阶段，受访者愿意治疗的家庭成员数量分别从4人增加到6人，费用为320.00奈拉（2.52美元）。发现性别因素会影响受访者感知的平均治疗成本；女性希望花费300.00奈拉（2.36美元），而男性则希望花费100.00奈拉（0.79美元）。
需要持续努力确保所有家庭都能负担得起吡喹酮药物，以实现尼日利亚流行社区控制感染的最终目标。
